The 3.5-Year Mortality Impact of Drugs in Secondary Prevention of Myocardial Infarction in Real-Life (Interim Analysis of the EOLE Cohort)

C. Droz, C. Dureau, D. Thomas, N. Danchin, J. Tricoire, J. Benichou, F. Paillard, S. Hercberg, I. Sibon, F. Rouanet, S. Rambelomanana, H. Maizi, M.A. Bernard, P. Blin, N Moore
Value in Health. 2014-11-01; 17(7): A476
DOI: 10.1016/J.JVAL.2014.08.1366


Read on PubMed

---

1. Value Health. 2014 Nov;17(7):A476. doi: 10.1016/j.jval.2014.08.1366. Epub 2014
Oct 26.

The 3.5-Year Mortality Impact Of Drugs In Secondary Prevention Of Myocardial
Infarction In Real-Life (Interim Analysis Of The Eole Cohort).

Droz C(1), Dureau C(2), Thomas D(3), Danchin N(4), Tricoire J(5), Benichou J(6),
Paillard F(7), Hercberg S(8), Sibon I(9), Rouanet F(9), Rambelomanana S(2), Maizi
H(2), Bernard MA(2), Blin P(2), Moore N(10).

Author information:
(1)INSERM CIC Bordeaux CIC 1401, Univ. Bordeaux, INSERM U657, Bordeaux, France.
(2)INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France.
(3)Hôpital Pitié Salpétrière, Paris, France.
(4)Hôpital Européen Georges Pompidou, Paris, France.
(5)Clinique Ambroise Paré, Toulouse, France.
(6)CHU de Rouen, INSERM U657, Rouen, France.
(7)CHU de Pontchaillou, Rennes, France.
(8)INSERM U557, Bobigny, France.
(9)CHU de Bordeaux, Bordeaux, France.
(10)INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, INSERM U657, CHU Bordeaux,
Bordeaux, France.

DOI: 10.1016/j.jval.2014.08.1366
PMID: 27201378

Know more about